Evidence that the shingles vaccine prevents a good chunk of dementia cases (twitter.com)

Article summary

Researchers have found evidence that the shingles vaccine may prevent a significant number of dementia cases. The study analyzed data from Wales, where a cutoff date was used to determine eligibility for the vaccine, and found a significant decrease in dementia rates in the population that received the vaccine. The findings suggest that the shingles vaccine may have a prophylactic effect against dementia and that Alzheimer's disease may be caused by a virus. The study's results are based on a preprint and have not been peer-reviewed.

Main themes

• shingles vaccine and dementia
• viruses and Alzheimer's disease
• mRNA vaccines and immunity
• funding and priorities for medical research
• energy transition and reduction of fossil fuel use
• complexity of viral infections and dementia

What commenters say

• The shingles vaccine may have a significant impact on reducing dementia cases, particularly in women who are at higher risk of developing Alzheimer's disease.
• The link between viruses and dementia is still being researched, with some commenting that HSV-1/2 may also be implicated in the development of Alzheimer's.
• mRNA vaccines may be more effective in targeting specific gene sequences and providing broader immunity, but others argue that they may not be as effective in the long term due to the potential for viral mutations.
• The development of vaccines and treatments for diseases like Alzheimer's and HSV-1/2 is hindered by a lack of funding and resources, with some commenting that military spending and other priorities take precedence over medical research.
• The transition to new energy sources and reduction of fossil fuel use is a complex issue that requires a multifaceted approach, including investment in nuclear power and other alternatives.
• The relationship between viruses and dementia is complex, and more research is needed to fully understand the causes and potential treatments for Alzheimer's disease.
• The use of mRNA vaccines may have advantages in terms of rapid development and deployment, but also raises concerns about the potential for viral mutations and the need for ongoing research and adaptation.